Last reviewed: May 12, 2026
Last updated: May 12, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone that plays a crucial role in glucose metabolism. Released by the intestines in response to food intake, GLP-1 stimulates insulin secretion, inhibits glucagon release, and slows gastric emptying. These actions contribute to better bl
Key Players in the GLP-1 Market
As the demand for effective weight management solutions grows, several pharmaceutical companies have emerged as leaders in the development of GLP-1 medications. Let’s explore the major players in this market:
Novo Nordisk is a pioneer in the field of GLP-1 drugs, having introduced the first medication, Byetta, to the market. The company has since expanded its portfolio with Victoza (liraglutide), Ozempic (semaglutide), and Wegovy (semaglutide). Wegovy, in particular, has gained widespread acclaim for its remarkable efficacy in weight loss, showing an average weight reduction of nearly 15% in clinical trials.
Eli Lilly has made significant strides in the GLP-1 market with its product Tirzepatide , marketed as Zepbound . This medication has shown impressive results, with participants experiencing weight loss exceeding 20% in clinical trials. Eli Lilly’s commitment to research and development has positioned the company as a formidable competitor to Novo Nordisk.
While AstraZeneca initially attempted to develop its own GLP-1 drugs, the company has pivoted towards licensing agreements. In 2023, AstraZeneca acquired a promising experimental weight-loss pill from a Chinese company, Eccogene. By investing in innovative assets, AstraZeneca seeks to establish a foothold in the GLP-1 market.
Amgen is another key player exploring the GLP-1 market. Their recent development of MariTide , a drug that aims to offer monthly dosing, could revolutionize the patient experience by reducing the frequency of injections. This innovative approach could make GLP-1 therapies more accessible to a broader audience.
The Impact of GLP-1 Drugs on Weight Management
GLP-1 drugs have emerged as a game-changer in the realm of weight management. Clinical studies have consistently demonstrated significant weight loss in individuals using these medications. For instance, the results from the clinical trials of Wegovy have shown an average weight reduction of around 15-20%, making it one of the most effective options available today.
As GLP-1 drugs gain popularity, accessibility remains a critical factor. Companies like Novo Nordisk and Eli Lilly are implementing direct-to-consumer (DTC) strategies to streamline the process of obtaining these medications. By facilitating access through telehealth platforms and personalized support, these companies are enhancing the patient experience.
While GLP-1 medications are generally well-tolerated, some patients may experience side effects such as nausea or gastrointestinal discomfort. Companies are actively working to address these concerns by providing education and support to help patients manage potential side effects.
The Future of GLP-1 Drugs
As awareness of GLP-1 medications continues to rise, the potential patient base is expanding. Research suggests that by 2030, approximately 30 million individuals in the U.S. may utilize GLP-1 therapies, representing about 9% of the population. This growth is fueled by an increased understanding of obesity as a chronic disease and the effectiveness of GLP-1 drugs in managing it.
The future of GLP-1 drugs looks promising, with ongoing research into oral formulations and combination therapies. Companies are exploring the development of oral GLP-1 medications that could offer the same benefits as injections while enhancing convenience for patients.
Collaboration between pharmaceutical companies and healthcare providers is essential for advancing GLP-1 therapies. By working together, these stakeholders can foster innovation, improve patient outcomes, and ensure that individuals receive the personalized care they need.
FAQ
Which companies are leading the GLP-1 market?
How effective are GLP-1 drugs for weight loss?
Are there side effects associated with GLP-1 drugs?
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider a pharmacogenomic foundation before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from 503B-registered outsourcing facilities meeting federal CGMP standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What are GLP-1 drugs used for?
GLP-1 drugs are primarily used for managing type 2 diabetes and for weight loss in individuals with obesity or overweight conditions. They help regulate blood sugar and promote weight loss by reducing appetite.
Which companies are leading the GLP-1 market?
The leading companies in the GLP-1 market include Novo Nordisk, Eli Lilly, AstraZeneca, Amgen, and Hanmi Pharmaceutical.
How effective are GLP-1 drugs for weight loss?
Clinical studies have shown that GLP-1 drugs can result in significant weight loss, with some medications demonstrating an average reduction of 15-20% of body weight.
Are there side effects associated with GLP-1 drugs?
While GLP-1 medications are generally well-tolerated, some individuals may experience side effects such as nausea, vomiting, or gastrointestinal discomfort. It’s important to consult with a healthcare provider for guidance on managing these effects.
How can I access GLP-1 medications?
GLP-1 medications typically require a prescription from a healthcare provider. Companies are increasingly offering telehealth services to facilitate access and provide personalized support to patients.
Related Reading
Pricing and availability current as of May 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Does GLP-1 Cause Osteoporosis? Exploring the Connection Between GLP-1 Medications and Bone Health
How Deep to Inject Semaglutide for Optimal Results